Switchable Retargeting of Lentiviral Vectors Through a VSV-G-Binding Adapter Molecule
Viruses · 2025
DOI: 10.3390/v17121563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Vladislav A Zhuchkov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia. Hauptthemen laut MEDLINE: Lentivirus, Genetic Vectors, Viral Envelope Proteins, Membrane Glycoproteins. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Federal scientific and technical program.
Abstract (Originalsprache)
Selective gene delivery to defined cell populations remains one of the key challenges in lentiviral vector-based gene therapy. The vesicular stomatitis virus glycoprotein (VSV-G) confers high infectivity but lacks cell-type specificity because of the ubiquitous expression of its receptor, LDLR. To enable modular, receptor-specific targeting while retaining the production efficiency of VSV-G-pseudotyped vectors, we designed a bispecific adapter, 929-B6, comprising a VSV-G-binding nanobody and an ERBB2-binding DARPin 9.29. Anti-VSV-G nanobodies were isolated from an alpaca immune library and screened in cell-based pseudoreceptor assays to identify the optimal binder (VSVG-B6). The resulting adapter was evaluated with receptor-ablated (VSV-Gmut) and wild-type VSV-G-pseudotyped LVs across ERBB2-positive and -negative cell lines and in a mouse xenograft model. 929-B6 enabled efficient, receptor-specific transduction of ERBB2-expressing cells without increasing infection of ERBB2-negative controls. Pre-incubation of VSV-Gmut-pseudotyped LVs with 1–2 µg/mL 929-B6 increased transduction up to eight-fold in ERBB2+ cells, with similar but smaller effects for VSV-G and VSV-Gmut + 929R pseudotypes. Across breast cancer lines, transduction enhancement correlated with ERBB2 surface density, and co-culture experiments confirmed selective entry into ERBB2+ populations. In vivo imaging of ERBB2+ tumors revealed a visible tumor-localized luminescent signal following administration of 929-B6-treated vectors. The 929-B6 adapter provides a rapid, scalable means to retarget standard LV stocks toward chosen receptors without re-engineering the envelope or co-packaging pseudoreceptor plasmids. Its modularity suggests a generalizable platform for both gene therapy and oncolytic applications requiring flexible, receptor-defined tropism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
- Biomarker Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
ORCID-Profile: Vladislav A Zhuchkov, Marat P Valikhov, Elena I Frolova, Stepan P Chumakov
Förderung
- Russian Science Foundation
- Federal scientific and technical program
Zitieren
APA
Zhuchkov, V. A., Valikhov, M. P., Kravchenko, Y. E., Frolova, E. I., & Chumakov, S. P. (2025). Switchable Retargeting of Lentiviral Vectors Through a VSV-G-Binding Adapter Molecule. Viruses. https://doi.org/10.3390/v17121563
Vancouver
Zhuchkov VA, Valikhov MP, Kravchenko YE, Frolova EI, Chumakov SP. Switchable Retargeting of Lentiviral Vectors Through a VSV-G-Binding Adapter Molecule. Viruses. 2025. doi:10.3390/v17121563
BibTeX
@article{Zhuchkov2025,
author = {Zhuchkov, Vladislav A and Valikhov, Marat P and Kravchenko, Yulia E and Frolova, Elena I and Chumakov, Stepan P},
title = {Switchable Retargeting of Lentiviral Vectors Through a VSV-G-Binding Adapter Molecule},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17121563}
}
EUVIMED